A number of research firms have changed their ratings and price targets for Dimension Therapeutics (NASDAQ: DMTX): 11/16/2015 – Dimension Therapeutics is now covered by analysts at Canaccord Genuity. They set a “buy” rating and a $20.00 price target on the stock. 11/16/2015 – Dimension Therapeutics is now covered by analysts at Goldman Sachs. They […]
